12342
document
The effect of topical nasal fluticasone on objective sleep testing and the symptoms of rhinitis , sleep , and daytime somnolence in perennial allergic rhinitis . Recent data suggested that daytime somnolence in patients with allergic rhinitis was secondary to disrupted sleep caused by nasal congestion . Medications , which decreased congestion , would be expected to improve sleep and daytime somnolence . Previously , we showed that nasal steroids improved all three symptoms . Presently , we have not performed objective sleep testing to determine if there is a correlation between subjective improvement of congestion , sleep , and daytime somnolence . The objective of this 8-week , double-blind , placebo-controlled study was to determine if topical nasal fluticasone is effective at decreasing subjective congestion and daytime somnolence and improving sleep and if this improvement correlated with a change in overnight sleep testing ( polysomnography ) . We recruited 32 subjects with perennial allergic rhinitis and randomized them in a double-blinded , cross-over fashion , to receive placebo or fluticasone ( 50 micrograms a spray ) , 2 sprays each side everyday , using Balaam 's design . Questionnaires , quality of life instruments , daily diary , Epworth Sleepiness Scale , and an overnight sleep test with polysomnograms were used as tools . The last 2 weeks of each 4-week treatment period were summarized , scored , and compared by PROC MIXED in SAS . Correlations between arousals on sleep tests and subjective tests were performed . Fluticasone improved subjective sleep when compared with placebo ( p = 0.04 ) ; however , there was no difference in the apnea/hypopnea index in those that were treated . Daytime sleepiness and fatigue were decreased by > 10 % in the treated group ; however , this was not statistically significant . However , fluticasone used at approved doses improves subjective sleep in patients with perennial allergic rhinitis without a change in the apnea/hypopnea index .
12343
Intervention_Pharmacological
fluticasone
12344
Intervention_Control
placebo-controlled
12345
Intervention_Pharmacological
fluticasone
12346
Intervention_Control
placebo
12347
Intervention_Pharmacological
fluticasone
12348
Outcome_Physical
objective sleep testing
12349
Outcome_Physical
symptoms of rhinitis , sleep , and daytime somnolence
12350
Outcome_Physical
disrupted sleep
12351
Outcome_Physical
sleep and daytime somnolence
12352
Outcome_Physical
improvement of congestion , sleep , and daytime somnolence
12353
Outcome_Physical
subjective congestion
12354
Outcome_Physical
daytime somnolence
12355
Outcome_Physical
improving sleep
12356
Outcome_Other
overnight sleep testing
12357
Outcome_Physical
( polysomnography
12358
Outcome_Other
Questionnaires
12359
Outcome_Other
quality of life instruments , daily diary
12360
Outcome_Other
Epworth Sleepiness Scale , and an overnight sleep test with polysomnograms
12361
Outcome_Physical
sleep tests and subjective tests
12362
Outcome_Physical
subjective sleep
12363
Outcome_Physical
apnea/hypopnea index
12364
Outcome_Physical
Daytime sleepiness
12365
Outcome_Physical
fatigue
12366
Outcome_Physical
subjective sleep
12367
Participant_Condition
perennial allergic rhinitis .
12368
Participant_Condition
allergic rhinitis
12369
Participant_Sample-size
32
12370
Participant_Condition
perennial allergic rhinitis
12371
Participant_Condition
perennial allergic rhinitis